ABSTRACT
Objectives The aim of this review was to analyse the implementation and impact of remote home monitoring models (virtual wards) during COVID-19, identifying their main components, processes of implementation, target patient populations, impact on outcomes, costs and lessons learnt.
Design The review was designed as a rapid systematic review to capture an evolving evidence base. We used the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement.
Setting The review included models led by primary and secondary care across seven countries.
Participants 17 examples of models were included in the review.
Main outcome measures Impact of remote home monitoring on virtual length of stay, escalation, emergency department attendance/reattendance, admission/readmission and mortality.
Results The aim of the models was to maintain patients safe in the right setting. Most models were led by secondary care and confirmation of COVID-19 was not required (in most cases). Monitoring was carried via online platforms, paper-based systems with telephone calls or (less frequently) through wearable sensors. Models based on phone calls were considered more inclusive. Patient/carer training was identified as a determining factor of success. We could not reach conclusions regarding patient safety and the identification of early deterioration due to lack of standardised reporting and missing data. Economic analysis was not reported beyond how the resources were used.
Conclusions Future research should focus on staff and patient experiences of care and inequalities in patients’ access to care. Attention needs to be paid to the cost-effectiveness of the models and their sustainability, evaluation of their impact on patient outcomes by using comparators and the use of risk-stratification tools.
Protocol registration The review protocol was published on PROSPERO (CRD: 42020202888).
Competing Interest Statement
NJF, ST, TG, CSJ, CVP, MS, KS had financial support for the submitted work from NIHR (Health Services and Delivery Research, 16/138/17 Rapid Service Evaluation Research Team; The Birmingham, RAND and Cambridge Evaluation (BRACE) Centre Team (HSDR16/138/31) and NJF is an NIHR Senior Investigator; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the HS&DR, NIHR, NHS or the Department of Health and Social Care.
Clinical Protocols
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=202888
Funding Statement
NJF, ST, TG, CSJ, CVP, MS, KS had financial support for the submitted work from NIHR (Health Services and Delivery Research, 16/138/17 Rapid Service Evaluation Research Team; The Birmingham, RAND and Cambridge Evaluation (BRACE) Centre Team (HSDR16/138/31) and NJF is an NIHR Senior Investigator; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the HS&DR, NIHR, NHS or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A this is a systematic review
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
c.vindrola{at}ucl.ac.uk.
k.e.singh{at}bham.ac.uk.
m.s.sidhu{at}bham.ac.uk.
theo.georghiou{at}nuffieldtrust.org.uk.
chris.sherlaw-johnson{at}nuffieldtrust.org.uk
s.tomini{at}ucl.ac.uk
matthew.inada-kim{at}nhs.net.
Karen.kirkham{at}dorsetccg.nhs.uk.
allison.streetly{at}phe.gov.uk
n.fulop{at}ucl.ac.uk
Abstract and title updated. Minor changes to the methods section.
Data Availability
All of the relevant data are included in the manuscript and supplementary files.
